Article Text

Download PDFPDF
OP 014
  1. Miriam Krischke1,
  2. Alan V Boddy2,
  3. Georg Hempel3,
  4. Swantje Völler3,
  5. Nicolas André4,
  6. Mauricio D'Incalci5
  1. 1University hospital Muenster, Centre for Clinical Trials (ZKS) Münster, Münster, Germany
  2. 2Newcastle University, Northern Institute for Cancer Research, Newcastle, UK
  3. 3Westfälische Wilhelms-Universität Münster, Department of Pharmaceutical and Medical Chemistry-Clinical Pharmacy, Münster, Germany
  4. 4Centre Hospitalier Universitaire, AP-HM, Marseille, France
  5. 5Department of Oncology Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy


Background Doxorubicin is a key component of a number of treatment regimens used in paediatric oncology. The pharmacology data on which current dosing regimens are based are very limited.

Methods We conducted a multicentre, multinational pharmacokinetic study investigating age-dependency in the clearance of doxorubicin in children with solid tumours and leukaemia. Blood samples for measurement of doxorubicin and its metabolite doxorubicinol were collected after 2 administrations, with 5 samples collected in children 3 yrs. A population pharmacokinetic approach was used for analysis, including pharmacogenetic covariates. NT-proBNP and cardiac troponin T were measured to evaluate their role as early indicators of cardiotoxicity.

Results 101 children could be recruited including 27 patients less than 3 years and among those 5 infants younger than 1 year. Overall, the patient acceptance of the trial was very good.

Age dependence of doxorubicin clearance was demonstrated, with children less than 3 years having a lower clearance (21.1±5.8 l/h/m2) than older children (26.6±6.7 l/h/m2) (p=0.0004), after correcting for body weight. Pharmacogenetic variants, including those in transporters and drug metabolizing enzymes, had little influence on pharmacokinetic parameters.

Natriuretic peptides plasma levels increased significantly shortly after doxorubicin administration, whereas cardiac troponin levels increased only with the administered cumulative anthracycline dose. Only limited correlation could be observed between their blood levels and doxorubicin pharmacokinetics.

Conclusion The paediatric need concerning missing PK-data could be addressed with limited burden for the patients. Empirically used dose adaptations for infants were found to be justified based on our PK analyses.

  • ESDP

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.